Nouscom

Nouscom is a privately held oncology company headquartered in Basel, Switzerland, that is developing next-generation cancer immunotherapies. Founded in 2015 by a team of experienced leaders from the pharmaceutical and biotech industries, Nouscom has developed a proprietary technology platform that harnesses the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators. This unique approach focuses on using engineered viral vectors to deliver neoantigens to the immune system, triggering a potent anti-tumor response.

The company's current clinical pipeline includes two promising programs: NOUS-209, an "off-the-shelf" immunotherapy for mismatch repair deficient (dMMR)/microsatellite instability (MSI) tumors, and NOUS-PEV, a personalized neoantigen cancer vaccine. Nouscom's deep knowledge of vaccine manufacturing allows them to design and manufacture their personalized vaccines quickly, making them a leader in the field of cancer immunotherapy.

Nouscom is a next-generation immunotherapy company developing engineered viral vectored vaccines to treat cancer. The company's mission is to generate safe, innovative, and potent cancer immunotherapies that selectively eliminate tumor cells. Their proprietary platforms utilize a portfolio of uniquely engineered viral vectors optimized to efficiently express long strings of tumor neoantigens, ultimately inducing broad and potent anti-tumor T cell responses.

Nouscom fosters a collaborative and innovative culture where diverse perspectives and expertise are valued. The company is characterized by a strong commitment to scientific excellence and a passion for developing groundbreaking cancer immunotherapies. With a seasoned leadership team, Nouscom prioritizes mentorship and professional development, creating an environment where employees feel empowered to contribute their best work.